New drug combination shrinks tumours in over 60 percent of patients with aggressive pancreatic cancer

Pairing an experimental pill with standard chemotherapy shrank tumours or halted their growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented on Friday at the EORTC-NCI-AACR Symposium in Barcelona.
The phase 1/2 trial tested a daily oral medication called daraxonrasib alongside two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. It involved 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.
Pancreatic cancer is notoriously difficult to treat because, research shows, more than half of patients are diagnosed after the disease has already spread. In major trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumours in about 23 to 42 percent of patients, but the disease typically begins growing again after five to six months, and most patients survive between 8 and 11 months. According to National Cancer Institute data, only about 3 percent of patients with distant-stage disease live five years past diagnosis.
In the new study, which tracked patients for a median follow-up of 18 months, tumours shrank in 60.7 percent of cases, including 8.2 percent where they disappeared entirely on scans. Overall, the combination stopped tumour growth in 90.2 percent of participants.
Patients went a median of 12.8 months before their cancer worsened — almost double the timeframe typically seen with standard chemotherapy — and 76.6 percent were still alive at the one-year mark.
Study lead Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said in a press release: 'We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year.'
More than 90 percent of pancreatic cancers are driven by a faulty gene called RAS, which allows tumours to keep growing. Daraxonrasib is designed to turn off that growth signal — something scientists long thought was impossible to fix with medication.
Dr Elena Garralda, chair of the symposium and co-director of the clinical research programme at the Vall d'Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits.
Side effects included rash, diarrhoea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care. Only 5 percent of patients stopped treatment because of side effects tied to daraxonrasib.
Researchers emphasised that the findings carry limitations. This was an early-phase, single-group study involving 61 people, all of whom received the experimental combination. Without a direct comparison group receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival. The findings apply strictly to metastatic pancreatic cancer; RAS mutations also drive certain lung, colorectal and gynaecological cancers, and separate studies would be needed for those diseases.
The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib. To determine whether the early findings translate into a durable survival benefit, researchers have launched a larger, randomised Phase 3 trial called RASolute-303, which directly compares daraxonrasib — both on its own and combined with chemotherapy — against standard chemotherapy alone.



